[Federal Register Volume 84, Number 109 (Thursday, June 6, 2019)]
[Notices]
[Pages 26447-26448]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-11877]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: SpecGx 
LLC

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before August 5, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on February 1, 2019, SpecGx LLC, 3600 North 2nd Street, 
Saint Louis, Missouri 63147 applied to be registered as a bulk 
manufacturer of the following basic class of controlled substances:

------------------------------------------------------------------------
        Controlled substance            Drug code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid..........            2010  I
Tetrahydrocannabinols..............            7370  I
Codeine-N-oxide....................            9053  I
Dihydromorphine....................            9145  I
Difenoxin..........................            9168  I
Morphine-N-oxide...................            9307  I
Normorphine........................            9313  I
Norlevorphanol.....................            9634  I
Acetyl Fentanyl (N-(1-                         9821  I
 phenethylpiperidin-4-yl)-N-
 phenylacetamide).
Butyryl Fentanyl...................            9822  I
Fentanyl related-compounds as                  9850  I
 defined in 21 CFR 1308.11(h).
Amphetamine........................            1100  II
Methamphetamine....................            1105  II
Lisdexamfetamine...................            1205  II
Methylphenidate....................            1724  II
Nabilone...........................            7379  II
4-Anilino-N-phenethyl-4-piperidine             8333  II
 (ANPP).
Codeine............................            9050  II
Dihydrocodeine.....................            9120  II
Oxycodone..........................            9143  II
Hydromorphone......................            9150  II
Diphenoxylate......................            9170  II
Ecgonine...........................            9180  II
Hydrocodone........................            9193  II
Levorphanol........................            9220  II
Meperidine.........................            9230  II
Methadone..........................            9250  II
Methadone intermediate.............            9254  II
Dextropropoxyphene, bulk (non-                 9273  II
 dosage forms).
Morphine...........................            9300  II
Oripavine..........................            9330  II
Thebaine...........................            9333  II
Opium tincture.....................            9630  II
Opium, powdered....................            9639  II
Oxymorphone........................            9652  II
Noroxymorphone.....................            9668  II
Alfentanil.........................            9737  II
Remifentanil.......................            9739  II
Sufentanil.........................            9740  II
Tapentadol.........................            9780  II
Fentanyl...........................            9801  II
------------------------------------------------------------------------


[[Page 26448]]

    The company plans to manufacture bulk active pharmaceutical 
ingredients (APIs) for distribution to its customers.

    Dated: May 23, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-11877 Filed 6-5-19; 8:45 am]
 BILLING CODE 4410-09-P